Latest total revenue for PTLA: $120M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2020
Trailing 12 months ending Mar 2020
As of the most recent data (March 2020), PTLA shows a total revenue of $120M. That compares with $56M in the prior-year period — up 117.2% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PTLA's total revenue is now $120M (was $56M) — a 117.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Portola Pharmaceuticals is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. Portola Pharmaceuticals is at $120M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how PTLA stacks up against individual peers as well.
Tracking PTLA's total revenue over time shows whether Portola Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $56M in the prior-year period — up 117.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Portola Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $120M) with ownership activity and broader fundamentals.